Vitamin B12 (Methylcobalamin)

What Is Methylcobalamin?

Methylcobalamin is one of the two coenzyme forms of vitamin B12, the other being adenosylcobalamin. Cobalamin from food becomes bioavailable through release from dietary protein, intrinsic factor-mediated absorption, transport by haptocorrin or transcobalamin, cellular uptake, and enzymatic conversion into these two cofactor forms^[1].

Methylcobalamin, also known by the INN mecobalamin, acts as a cofactor for B12-dependent methyltransferases^[2]. It is also one of four vitamin B12 forms used commercially, alongside cyanocobalamin, hydroxocobalamin and 5′-deoxyadenosylcobalamin^[3].

Since its discovery, mecobalamin has been applied mainly to hyperhomocysteinemia and peripheral neuropathy^[2]. More recent research includes randomized trials in amyotrophic lateral sclerosis (ALS) and in chemotherapy-associated hand-foot syndrome^[4][5].

Chemical Structure and Molecular Identity

Methylcobalamin is a cobalt(III) corrinoid in which a methyl group is bonded directly to the cobalt atom, making it a naturally occurring organometallic compound. PubChem (CID 10898559) lists the molecular formula C63H91CoN13O14P and a molecular weight of 1344.4 g/mol. The CAS number is 13422-55-4.

The core is the same as in every cobalamin: a corrin macrocycle coordinating cobalt through four nitrogen atoms, with a 5,6-dimethylbenzimidazole nucleotide as the lower axial ligand. The forms differ only in the upper ligand. Methylcobalamin carries a methyl group where cyanocobalamin carries cyanide^[3].

Stability and analytical identification

The cobalt-carbon bond is the molecule’s weak point. Light cleaves it, and in the presence of oxygen methylcobalamin is converted to hydroxocobalamin. A 2022 review compared the reactivity of the four commercial B12 forms under temperature, pH and light, and in the presence of oxidants, reductants and other water-soluble vitamins, and evaluated stabilization approaches^[3].

For identity and purity, laboratories typically use reversed-phase HPLC with visible-UV detection, often confirmed by mass spectrometry, and handle samples under light protection. Hydroxocobalamin and cyanocobalamin are the main related substances to separate and quantify.

Research History and Development

Methylcobalamin research moved from cofactor biochemistry to clinical studies in homocysteine disorders and neuropathy, and later to randomized trials in ALS. A 2008 review covered its mechanism, pharmacokinetics and metabolism, and its clinical use as monotherapy or combined therapy in hyperhomocysteinemia and peripheral neuropathy^[2].

A 1998 monograph argued that methylcobalamin had a theoretical advantage over cyanocobalamin and some metabolic applications not shared by other B12 forms, and listed proposed areas of interest ranging from diabetic neuropathy to sleep disorders^[6]. Such claims were largely untested by large controlled trials at the time.

In ALS, a long-term phase II/III randomized controlled study tested ultra-high-dose methylcobalamin against placebo^[4]. The ALSUntangled group reviewed the evidence on methylcobalamin in 2015^[7], and a later multicenter phase 3 trial in Japan focused specifically on patients enrolled within one year of symptom onset^[8].

Mechanisms Studied in Research

The established biochemical role of methylcobalamin is as the methyl-carrying cofactor of B12-dependent methyltransferases; additional neural mechanisms have been proposed from experimental studies. In humans, cobalamin is converted via methionine synthase and methylmalonyl-CoA mutase into its two cofactor forms^[1].

Proposed neural mechanisms include:

• Nerve regeneration and neuroprotection: promoting regeneration of injured nerves and antagonizing glutamate-induced neurotoxicity^[9].
• Reduced ectopic firing: inhibiting spontaneous ectopic discharges of injured primary sensory neurons^[9].
• Ion channel modulation: decreasing excitability in medium-sized dorsal root ganglion neurons and the expression of TRPA1, TRPM8, TRPV1, TRPV4, phosphorylated p38 MAPK and axonal voltage-gated sodium channels^[10].
• Immune modulation: effects on T lymphocytes, natural killer cells and cytokines such as TNF-alpha, IL-6 and IL-1beta^[10].

A 2020 systematic review summarized the proposed basis for B12 in neuropathic pain as promoting myelination, increasing nerve regeneration and decreasing ectopic nerve firing^[11]. A 2013 review added that methylcobalamin alleviated pain behaviors in experimental and clinical studies of diabetic neuropathy, low back pain and neuralgia, and improved nerve conduction^[9]. Most of these mechanisms come from animal and cell studies.

Key Findings From Published Studies

Randomized trials of methylcobalamin have produced positive results in some neuropathy and supportive-care settings and mixed results in ALS.

Neuropathy

In a 1-year double-blind trial in 90 adults with type 2 diabetes on long-term metformin, diabetic neuropathy and B12 levels below 400 pmol/L, oral methylcobalamin raised B12 levels and improved vibration perception threshold, sural nerve conduction, pain scores and quality of life compared with placebo, while several measures worsened in the placebo group^[12]. A 2008 review reported that mecobalamin monotherapy and combined therapy both lowered plasma or serum homocysteine and improved neuropathic symptoms, with combinations with other B vitamins appearing more effective^[2]. A 2025 meta-analysis of seven randomized trials of dapagliflozin combined with methylcobalamin in diabetic peripheral neuropathy reported improved overall effective rate and nerve conduction velocities^[13]. A 2020 systematic review of 24 studies found some evidence for B12 in post-herpetic neuralgia (level II) and painful peripheral neuropathy (level III)^[11].

Amyotrophic lateral sclerosis

In the phase II/III study of 373 patients, which compared two methylcobalamin dose levels with placebo, neither primary endpoint (time to death or full ventilation support, and change in ALSFRS-R score) differed significantly. Post-hoc analyses of patients enrolled within 12 months of onset showed a longer time to primary events and smaller ALSFRS-R decline, and treatment-related adverse events were similar and low across groups^[4].

The follow-up phase 3 trial enrolled patients diagnosed within one year of onset and, after a 12-week observation period, randomized 130 of them to methylcobalamin or placebo for 16 weeks, with change in ALSFRS-R total score as the primary endpoint^[8].

Hand-foot syndrome

In a 2025 phase 3 trial in 234 women receiving adjuvant capecitabine for HER2-negative early breast cancer, grade 2 or higher hand-foot syndrome occurred in 14.5% of the oral methylcobalamin group and 29.1% of the placebo group, with no methylcobalamin-specific adverse events^[5]. Reduction or discontinuation of capecitabine because of hand-foot syndrome occurred in 7.7% versus 13.7%, a difference whose confidence interval included zero^[5].

Because methylcobalamin’s cobalt-carbon bond is light-sensitive, researchers typically confirm identity and purity, including hydroxocobalamin content, with HPLC and mass spectrometry certificates of analysis.

Because methylcobalamin's cobalt-carbon bond is light-sensitive, researchers typically confirm identity and purity, including hydroxocobalamin content, with HPLC and mass spectrometry certificates of analysis.

Regulatory and Research Status

Methylcobalamin is not an FDA-approved drug in the United States, although mecobalamin is approved as a prescription drug in Japan. Cyanocobalamin, not methylcobalamin, is the B12 form used in US-approved prescription products.

Reviewers continue to call for better evidence. The 2008 mecobalamin review concluded that more precise double-blind randomized trials were needed to confirm effects on hyperhomocysteinemia, peripheral neuropathy and cardiovascular, neurological and osteoporotic outcomes^[2]. Diagnostic questions also complicate research: serum B12 remains the most common test, but holotranscobalamin, methylmalonic acid and homocysteine are increasingly used, and test limitations can lead to inappropriate treatment decisions^[1].

For researchers, open questions include which patient subgroups benefit in ALS and neuropathy, and how stability differences between B12 forms affect product quality^[3].